Immunis Revenue and Competitors

Immunis Inc. is a private, clinical-stage biotechnology company developing stem cell-derived biologics to address age-related diseases and immune dysfunction. The secretome is the total set of factors secreted by a cell. A well-functioning immune system is necessary for our health and secretomes can refine immune cell responses, making them a promising therapeutic for autoimmune, neurodegenerative and age-related muscle wasting diseases (sarcopenia). \n\nOur investigational secretome, IMM01-STEM, includes a balance of all-natural, clinical-grade factors that benefit immune system development, modulation, and health. Immunis’ published pre-clinical data in GeroScience demonstrates that IMM01-STEM benefits muscle regeneration, mass, and function. Immunis published additional data in Aging Cell showing that IMM01-STEM increases whole-body lean mass and reduces fat mass, while increasing muscle size, enhancing muscle regeneration and improving muscle function. \n\n100% of humans develop sarcopenia with age, which significantly impairs mobility and compromises quality of life. Preventing muscle loss and improving muscle recovery are currently unfulfilled medical needs. Immunis' first Phase 1/2a clinical study tested the safety, tolerability, and preliminary efficacy of IMM01-STEM in elderly individuals who have age-related muscle atrophy associated with knee osteoarthritis.\n\nImmunis is currently conducting a Phase 2 clinical trial testing IMM01-STEM's safety and efficacy in patients with sarcopenic obesity. Obesity rates have skyrocketed within the past few decades, with a heavy impact on the elderly population. Age-related obesity is strongly linked with additional health concerns including diabetes and muscle loss, which can have detrimental effects on quality of life. \n\n“Our innovative therapy shows promising results by simultaneously decreasing fat and enhancing muscle,” explains Chairman Dr. Keirstead.